TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12673176
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of I‐123 MIBG heart‐mediastinal ratio and HRV 5‐minute low‐frequency variables
Study: 27179988
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg loading dose followed by 81 mg/d)
Study: 20592433
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d)
Study: 18588848
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 microg administered vaginally twice, 6 and 12 hours before hysteroscopy
Study: 18588848
Drug: Placebo (hexetidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hexetidine pill) administered vaginally twice, 6 and 12 hours before hysteroscopy
Study: 16087019
Drug: Injection snoreplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection snoreplasty (IS)
Study: 12544159
Drug: Home interferential
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home interferential current therapy (IFC)
Study: 10479130
Drug: Protease inhibitor-containing
Normalized name: Protease inhibitor-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-containing triple therapy for 2 years
Study: 1891022
Drug: Controlled-release aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release aspirin (75 mg, releasing 10 mg per hour)
Study: 1891022
Drug: Immediate-release aspirin
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release aspirin (162.5 mg loading dose)
Study: 1891022
Drug: Immediate-release aspirin
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release aspirin (75 mg)
Study: 1891022
Drug: Controlled-release aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release aspirin (75 mg)
Study: 6215855
Drug: Bound niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bound niacin (BN) - 35 mg niacin
Study: 6215855
Drug: Alkali-treated bound
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkali-treated bound niacin (ABN) - 24 mg pure nicotinic acid
Study: 6215855
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid - 24 mg
Study: 28847468
Drug: slow‐release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow‐release melatonin at a dose of 3mg
Study: 24477842
Drug: Toothpaste B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste B (0.454% SnF2, Oral-B(®))
Study: 24477842
Drug: SnF2 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnF2 solution (0.4%, 1,000 ppm F)
Study: 20363764
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel loading 4-8 hours before PCI
Study: 16116130
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid drink containing l-tryptophan
Study: 16116130
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid drink omitting l-tryptophan
Study: 8918516
Drug: Al(OH)3 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al(OH)3 (one tablet three times a day, about 302 mg aluminium day‐1) for 3 months
Study: 8918516
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 patients receiving no Al‐containing agents)
Study: 1907681
Drug: phenytoin suspension
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phenytoin suspension alone
Study: 6440313
Drug: Gliclazide 40
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 40 mg
Study: 6440313
Drug: Glibenclamide 2.5
Normalized name: glibenclamide 2.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 2.5 mg
Study: 30807455
Drug: Observational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational treatment
Study: 30807455
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Antibiotic and Observational)
Study: 29968187
Drug: Adequate vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate vitamin D group (AVD; serum 25(OH)D > 50 nmol/l)
Study: 29968187
Drug: Inadequate vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate vitamin D group (IVD; serum 25(OH)D < 50 nmol/l)
Study: 26889974
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy
Study: 26889974
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy
Study: 22960817
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% cream as single application
Study: 22960817
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin 1% lotion as single application
Study: 22960817
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin 200 mcg/kg as single dose
Study: 20960535
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rosuvastatin (R) 5, 10, or 20 mg + fenofibric acid (FA) 135 mg
Study: 20960535
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid (FA) monotherapy
Study: 20960535
Drug: Rosuvastatin (R)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (R) monotherapy
Study: 17363756
Drug: Topiramate CR
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate CR (175 mg/day)
Study: 15712850
Drug: Coarse wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarse wheat bran (10-20 g/day)
Study: 12577231
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with radiation and 5-fluorouracil
Study: 12577231
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with gemcitabine
Study: 11334066
Drug: Erythromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (10 mg/kg IV)
Study: 11334066
Drug: Erythromycin (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (additional doses)
Study: 11334066
Drug: Placebo (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (additional doses)
Study: 9727545
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Ticlopidine and Aspirin)
Study: 8052456
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice cocktail (300 mL daily)
Study: 22725648
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg bolus, followed by continuous infusion of 20 μg/kg/min after intubation)
Study: 22725648
Drug: IV flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV flurbiprofen (1 mg/kg before skin incision)
Study: 22725648
Drug: IV parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: IV parecoxib (40 mg before skin incision)
Study: 11834117
Drug: Low-intensity resistance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity resistance exercise training with 3 sets at approximately 50% 1RM and 30 seconds interset rest, performed twice a week for 12 weeks.
Study: 10071990
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus usual medical therapy
Study: 2553326
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition
Study: 30813149
Drug: Glutamine (GLN)
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine (GLN) supplementation at a dose of 10g every 8 hours (prophylactic powdered GLN orally)
Study: 26450442
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (robot-assisted therapy plus intensive conventional therapy)
Study: 17957152
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (2.2 g DHA and 1.1 g EPA)
Study: 15891550
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (closed reduction and percutaneous pin fixation, open reduction and internal fixation, and arthrodesis)
Study: 15891550
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (elevation, ice, early mobilization, cyclic compression of the plantar arch)
Study: 24705867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both treatments
Study: 9987151
Drug: Vaginal mucosal
Normalized name: Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal mucosal vaccine for UTI
Study: 18803532
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of oral prednisolone (1 mg/kg)
Study: 10201583
Drug: Initial medications
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medications (n=307) with a stepped regimen to lower intraocular pressure
Study: 10201583
Drug: Initial medications
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medications (n=307)
Study: 30246286
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg/d
Study: 31126631
Drug: Doxycycline in
Normalized name: doxycycline Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline in combination with oral corticosteroids for 20 days
Study: 31126631
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with oral corticosteroids for 20 days
Study: 23726870
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for depression
Study: 12915334
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) supplementation, with a daily dose of up to 2.6 grams of fish oil (equivalent to about 1.6 grams of EPA)
Study: 11910618
Drug: Prototype patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype patch
Study: 11910618
Drug: Industrial counterpart
Normalized name: Counteract IB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Industrial counterpart patch
Study: 11910618
Drug: Reservoir patch
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reservoir patch (Estraderm TTS 50)
Study: 11910618
Drug: Reference matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference matrix patch (System 50)
Study: 7835364
Drug: Elevated anticardiolipin
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated anticardiolipin antibody (ACLA) titres (IgM and IgG)
Study: 7835364
Drug: Elevated anticardiolipin
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated anticardiolipin antibody (ACLA) titres (IgG)
Study: 7835364
Drug: Occurrence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occurrence of anti-heart muscle antibodies (AHA) > or = 2+
Study: 16911315
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of half-isotonic saline (1 mL/kg/h) for 12 h before surgery (hydration group)
Study: 16911315
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of half-isotonic saline (hydration group)
Study: 12796167
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug treatment (TDG) - albuterol, ipratropium bromide, and flunisolide
Study: 12796167
Drug: A/IB (albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/IB (albuterol and ipratropium bromide)
Study: 12796167
Drug: A/F (albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/F (albuterol and flunisolide)
Study: 10968813
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg hypericum extract ZE 117 twice daily for 6 weeks
Study: 10968813
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg imipramine twice daily for 6 weeks
Study: 1767901
Drug: Rectal cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal cisapride 30 mg and intramuscular morphine 10 mg
Study: 1767901
Drug: Rectal cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal cisapride 60 mg and intramuscular morphine 10 mg
Study: 1767901
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories and intramuscular morphine 10 mg
Study: 1767901
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories only
Study: 29066145
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (4 doses of 1 g over 15 minutes every 6 hours for 24 hours)
Study: 29066145
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo (saline placebo, equal volume to acetaminophen)
Study: 26875489
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg menaquinone-7 daily for 12 weeks (Study 2)
Study: 26875489
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg menaquinone-7 daily for 4 weeks (Study 1)
Study: 26875489
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg menaquinone-7 daily for 4 weeks (Study 1)
Study: 26875489
Drug: 0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg menaquinone-7 daily (Study 1)
Study: 19519874
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser (DL) and placebo gel
Study: 19519874
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser and NK10% gel
Study: 19519874
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser and placebo gel
Study: 17198098
Drug: Epinephrine-containing lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-containing lidocaine solution (40 microg, 2.5 microg/mL)
Study: 17198098
Drug: Epinephrine-containing lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-containing lidocaine solution (80 microg, 5 microg/mL)
Study: 17198098
Drug: Epinephrine-containing lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-containing lidocaine solution (160 microg, 10 microg/mL)
Study: 17198098
Drug: Epinephrine-containing lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-containing lidocaine solution (all groups)
Study: 15072808
Drug: Fluvoxamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (up to 300 mg per day) plus counselling and support
Study: 7663138
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg p.o.)
Study: 7663138
Drug: Isosorbide‐5‐mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (20 mg p.o.)
Study: 2660562
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g twice per day)
Study: 2660562
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg before bed)
Study: 22745189
Drug: Sulpiride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (400 mg, selective D2 antagonist)
Study: 16822120
Drug: Homework compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Homework compliance during cognitive-behavioral therapy (CBT)
Study: 8472110
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide (CO2) as the insufflation agent
Study: 8472110
Drug: Air as
Normalized name: OCTINOXATE 2010 mg in 30 mL / OCTOCRYLENE 900 mg in 30 mL / TITANIUM DIOXIDE 600 mg in 30 mL TOPICAL EMULSION [SHISEIDO SYNCHRO SKIN SELF-REFRESHING TINT 125 Fair Asterid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air as the insufflation agent
Study: 23845716
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography screening
Study: 27191255
Drug: Maxillary canine
Normalized name: CanineAid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary canine retraction using mini-implants as anchorage for approximately 4 months with 100g of force via coil springs.
Study: 27191255
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no orthodontic treatment).
Study: 19922572
Drug: Intramuscular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naloxone (2 mg)
Study: 10570736
Drug: Mechanical support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical support of minute ventilation for chronic but stable diseases (e.g., old polio, quadriplegia, kyphoscoliosis)
Study: 10570736
Drug: Mechanical support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical support of minute ventilation for chronic and progressive diseases (e.g., muscular dystrophy, amyotrophic lateral sclerosis)
Study: 7598463
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment of IDDM patients
Study: 7598463
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment recommendations
Study: 7598463
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of insulin in NIDDM patients
Study: 786832
Drug: Control (antiphologistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antiphologistic containing high dosage of vitamin B complex and Metamizol)
Study: 27387522
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (non-ASV)
Study: 25289711
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g L-carnitine
Study: 25289711
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g L-carnitine
Study: 22164964
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium enteric coated tablets (test formulation)
Study: 22164964
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium enteric coated tablets (reference formulation)
Study: 11096234
Drug: Intermittent hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent hormonal deprivation using luteinizing hormone-releasing hormone (LHRH) analogue alone (n = 11)
Study: 8354733
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 or 100 mg)
Study: 8354733
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 or 100 mg) + Ethanol (0.8 g/kg)
Study: 3564877
Drug: Bain system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bain system at VF of 125 ml X min‐1 X kg‐1 b.w.
Study: 3564877
Drug: Bain system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bain system at VF of 100 ml X min‐1 X kg‐1 b.w.
Study: 3564877
Drug: Lack system
Normalized name: allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack system at VF of 70 ml X min‐1 X kg‐1 b.w.
Study: 3564877
Drug: Lack system
Normalized name: allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack system at VF of 55 ml X min‐1 X kg‐1 b.w.
Study: 30513923
Drug: CPO (composite
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPO (composite supplement containing collagen peptide and ornithine)
Study: 20202953
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral indomethacin
Study: 10703539
Drug: GADA (glutamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: GADA (glutamic acid decarboxylase antibodies)
Study: 10703539
Drug: ICA (islet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICA (islet cell antibodies)
Study: 8697549
Drug: Rocuronium continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium continuous infusion starting at 0.6 mg.kg‐1.hr‐1, adjusted by 0.1 mg.kg‐1.hr‐1 to maintain one visible twitch of the TOF.
Study: 1757603
Drug: Halobetasol propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol propionate ointment
Study: 23528398
Drug: 1% emoxipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% emoxipine solution
Study: 23528398
Drug: 1.5% reamberin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% reamberin solution